RUOLO DELLA TERAPIA ANTIANGIOGENICA NEL CARCINOMA MAMMARIO Rilevanza delle Evidenze Scientifiche P Pronzato Modena, 18.11.2011.

Slides:



Advertisements
Similar presentations
Take home message Breast Cancer Bevacizumab in MBC Sabino De Placido 1.
Advertisements

Miles DW et al. SABCS 2009;Abstract 41.
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Oncologic Drugs Advisory Committee
Bevacizumab taxan Första linjens behandling vid metastaserande Her2- bröstcancer.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
Metastatic HER2-Positive Breast Cancer: Treatment Selection and Sequencing in the First Line and Beyond Moderator: Joseph Gligorov, MD, PhD Head, Cancer.
ECCO ESMO 2011 GI Cancer Updates “ VELOUR” Study Author: J Tabernero et al Reviewed by: Dr. Scott Berry Date posted: October.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
AVADO PFS Analysis (ITT Population) All P values vs. placebo Adapted from Miles et al. ASCO 2008, abstract LBA 1011.
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Registration Trial to Evaluate the Efficacy and Safety of Placebo + Trastuzumab + Docetaxel vs.
A Phase III study (EMBRACE. ) of eribulin mesylate vs
Bevacizumab: Antiangiogenic therapy for breast cancer: where do we stand? Fortunato Ciardiello Division of Medical Oncology, Department of Clinical and.
Effect of Age on Efficacy and Safety Outcomes in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Receiving Lenalidomide and Low-Dose Dexamethasone.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line human epidermal growth factor receptor.
Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.
Il punto di vista del clinico Fabio Puglisi, MD PhD Ruolo della terapia antiangiogenica nel carcinoma mammario.
RIBBON-1: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy with or without Bevacizumab for First-Line Treatment of HER2-Negative.
A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.
Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.
A Meta-Analysis of Overall Survival Data from Three Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Assistant Professor of Medicine Dana-Farber Cancer Institute
Targeting VEGF for the Treatment of Colorectal Cancer Herbert Hurwitz Duke University Medical Center Durham, North Carolina, USA.
Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)
CheckMate 025: A randomized, open-label, phase III study of nivolumab versus everolimus in advanced renal cell carcinoma Padmanee Sharma, Bernard Escudier,
Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.
Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
A Phase III Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer.
E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Pritchard KI et al. Proc SABCS 2010;Abstract P
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
OCEANS: A Randomized, Double- Blinded, Placebo-Controlled Phase III Trial of Chemotherapy with or without Bevacizumab (BEV) in Patients with Platinum-
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
Figure 1. Hazard ratios for progression-free survival analyzed with fixed effect model. Table 1: Relevant trials Table 2. Methodological quality Conclusions.
Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.
1 A Randomized, Multi-Center Phase III Trial of Irinotecan in Combination with Three Different Methods of Administration of Fluoropyrimidine with Celecoxib.
Reviewer: Dr Scott Berry Date posted: June 21, 2007 CAPEOX vs. FOLFOX4 +/- Bevacizumab: survival results from NO16966, a randomized.
Moskowitz CH et al. Proc ASH 2014;Abstract 673.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.
Pazopanib in Advanced Ovarian Cancer: A new galloping horse. Dr. Raafat Ragaie, MD,FRCR.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 GOG0213: Bevacizumab Retreatment of Recurrent Platinum-Sensitive Ovarian.
Y-K Kang, A Ohtsu, E Van Cutsem, SY Rha, A Sawaki SR Park, H-Y Lim, J Wu, B Langer, MA Shah on behalf of AVAGAST investigators AVAGAST: a randomized, double-blind.
CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.
ECCO ESMO 2011 GI Cancer Updates “VELOUR” Study
CCO Independent Conference Coverage
CCO Independent Conference Highlights
Alessandra Gennari, MD PhD
Azienda Ospedaliero Universitaria Policlinico Modena
ASCO 2002 Advances in the Adjuvant Chemotherapy of Breast Cancer
CCO Independent Conference Coverage
Vahdat L et al. Proc SABCS 2012;Abstract P
What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard
Swain SM et al. Proc SABCS 2012;Abstract P
Bevacizumab in platinum-sensitive ovarian cancer: OCEANS.
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
Baselga J et al. SABCS 2009;Abstract 45.
First efficacy and safety results from XELOX-1/NO16966, a randomised 2x2 factorial phase III trial of XELOX vs FOLFOX4 + bevacizumab or placebo in first-line.
1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada
Presentation transcript:

RUOLO DELLA TERAPIA ANTIANGIOGENICA NEL CARCINOMA MAMMARIO Rilevanza delle Evidenze Scientifiche P Pronzato Modena,

(Anti-) Angiogenesis

[TITLE]

HER2- Metastatic Breast Cancer (CT Needed) Decision Making Problems

F Cardoso & J Cortes

MBC: main drivers in 2010s Clinico Pathological Factors – HER2 /HR – Previous Treatment – Burden of Disease

MBC: main drivers in 2010s Goals – Prolongation of Survival – Quality of Life – Symptom Relief – Response – Delay of Progression Clinico Pathological Factors – HER2 /HR – Previous Treatment – Burden of Disease

MBC HER2 HER2- HER2+ HR+HR- After HT CHEMOTHERAPY Previous anthra-taxanes CT Evidence Based Decision Making HER2- / MBC

MBC HER2 HER2- HER2+ HR+HR- After HT CHEMOTHERAPY Previous anthra-taxanes CT Evidence Based Decision Making HER2- / MBC

[TITLE] MN Dickler, ASCO 2011

RCTs and Meta-Analysis

Survival Analyses Miller K et al. N Engl J Med 2007;357:

Hazard Ratios for Disease Progression Miller K et al. N Engl J Med 2007;357:

Hazard Ratios for Disease Progression Miller K et al. N Engl J Med 2007;357: Soon this regimen became widely adopted by clinicians who treated thousands of patients and felt confortable with using the drug AM Gonzalez-Angulo, Nat Rev Clin Oncol 2011

Trial Design Capecitabine (1000 mg/m 2 bid d1–14) Taxane (docetaxel 75–100 mg/m 2 or nab-paclitaxel 260 mg/m 2 ) Anthracycline-based chemotherapy AC (doxorubicin 50–60 mg/m 2, cyclophosphamide 500–600 mg/m 2 ) EC (epirubicin 90–100 mg/m 2, cyclophosphamide 500–600 mg/m 2 ) FAC (5-FU 500 mg/m 2, doxorubicin 50 mg/m 2, cyclophosphamide 500 mg/m 2 ) FEC (5-FU 500 mg/m 2, epirubicin 90–100 mg/m 2, cyclophosphamide 500 mg/m 2 ) Bevacizumab or placebo (15 mg/kg) Investigator’s choice of chemotherapy Capecitabine or taxane/ anthracycline Previously untreated MBC (n=1237) Stratification factors: Disease-free interval Previous adjuvant chemotherapy No. of metastatic sites Capecitabine, taxane or anthracycline Optional 2nd - line chemotherapy + bevacizumab Treat until PD RANDOMIZE 2:1 Robert et al. ASCO 2009 Chemotherapy + bevacizumab q3w Chemotherapy + placebo q3w NJ Robert, JCO 2011

IRC assessment Median, months HR (95% CI)*0.68 (0.54–0.86) p= Investigator assessment Median, months HR (95% CI)*0.69 (0.56–0.84) p= PFS: Capecitabine Cohort BV (n=409) PL (n=206) PFS estimate Months *Stratified analysis Robert et al. ASCO 2009 NJ Robert, JCO 2011

Objective Response Rate*: Capecitabine Cohort Patients, % p= *Patients with measurable disease at baseline Complete response Partial response Robert et al. ASCO 2009 NJ Robert, JCO 2011

A Meta-Analysis of Overall Survival Data from Three Trials of Bevacizumab and First-Line Chemotherapy as Treatment for Patients with Metastatic Breast Cancer Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, TX; Mount Vernon Cancer Centre, London, England; Dana-Farber Cancer Institute, Boston, MA; Institut Curie, Paris, France; Mayo Clinic, Jacksonville, Florida; Michiana Hematology Oncology, South Bend, IN; Vall d'Hebron University Hospital, Barcelona, Spain; BioOncology, Genentech, S San Francisco, CA; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN Joyce O’Shaughnessy, David Miles, Robert Gray, Véronique Diéras, Edith A. Perez, Robin Zon, Javier Cortés, Xian Zhou, See-Chun Phan, Kathy Miller ASCO, 2010

23 General Study Designs Optional Second- line Chemo + BV ( AVADO and RIBBON-1 only ) Chemo + No BV Chemo + BV Treat until PD RANDOMIZE Previously Untreated MBC RIBBON-1 Capecitabine, Taxane, or Anthracycline AVADO Docetaxel E2100 Paclitaxel

24 BV=bevacizumab, PL=placebo, PFS=progression-free survival, ORR=objective response rate, OS=overall survival. * Permitted continuing on BV or crossing over to BV. † Analyses based on IRF assessments. Comparison of the Studies E2100AVADO*RIBBON-1* No. of patients GeographyUS (90%)Ex-USUS (50%) Randomization ratio (BV:PL) 1:1 2:1 Chemotherapy Paclitaxel weekly Docetaxel Capecitabine, Docetaxel/nab-Paclitaxel, Doxorubicin/Epirubicin Primary EndpointPFS † PFS Key Secondary Endpoints OS, ORR OS, ORR, 1-yr survival

25 Overview of Efficacy Results from the Individual Studies in the Pooled Analysis E2100AVADO RIBBON-1 (Cape) RIBBON-1 (Tax/Anthra) Non- BV BV Non- BV BV* Non- BV BV Non- BV BV Median PFS, mo Stratified HR (95% CI) 0.48 (0.39–0.61) 0.62 (0.48–0.79) 0.69 (0.56–0.84) 0.64 (0.52–0.80) p-valuesp<0.0001p=0.0003p=0.0002p< BV=bevacizumab, Cape=capecitabine, Tax/Anthra=taxane/anthracycline. * 15 mg/kg cohort.

26 Patient Characteristics, Pooled Population Non-BV (n  1008) BV (n  1439) Age, median 55 yr56 yr Triple-negative disease, %2625 Disease-free interval (≤24 mo), %3937 Prior adjuvant chemo, %6462 Taxane2224 Anthracycline5248 Visceral disease, %7169 ≥3 metastatic sites, %3841

27 Progression-Free Survival, Pooled Population Non-BV (n=1008) BV (n=1439) Median, mo HR (95% CI)0.64 (0.57–0.71)

28 Analysis of PFS by Subgroups

29 Objective Response Rate* *Includes only patients with measurable disease at baseline. Non-BV (n=788) BV (n=1105) Objective response rate (%)

30 Overall Survival, Pooled Population Non-BV (n=1008) BV (n=1439) Median, mo HR (95% CI)0.97 (0.86–1.08) 1-yr survival rate (%) 7782

31 Use of Subsequent Systemic Therapies in AVADO and RIBBON-1 Studies* % Non-BV (n  654) BV (n  1071) Any chemotherapy7165 Bevacizumab5140 Any hormonal therapy2523 # of subsequent anti-cancer agents ≥ *Data not available from E2100.

32 Conclusions Significant PFS advantage but no OS difference with BV across 3 first-line studies and in pooled analysis -In MBC, the ability of Phase III trials to demonstrate treatment effect upon OS depends on the duration of survival post-progression (SPP) -Higher chance of affecting OS in populations with short SPP (20 month PPS in these 3 first-line trials) Patients with adverse prognostic features benefit from BV as do patients with more indolent disease Low incidence of treatment-related deaths with BV Safety profile consistent with previous BV experience Broglio and Berry J Natl Cancer Inst. 101: Saad, Katz, and Buyse J Clin Oncol. 28: Burzykowski, et al J Clin Oncol. 26:

A look at TNBC

34 [TITLE]

35 [TITLE]

Facts and Prejudices

Regrowth Toxicity Age Cost

D Miles, JCO 2011 From discontinuation to death

V Ranpura, JAMA 2011 Bevacizumab and FAEs

V Ranpura, JAMA 2011

T Choueiri, JCO 2011 Bevacizumab and CHF

44 Safety, Causes of Death* % Non-BV (n  982) BV (n  1679) Total deaths MBC Treatment-related Other Missing *Safety evaluable patient population.

45 Grade ≥3 Selected Adverse Events (AEs), Pooled Population % Non-BV (n  982) BV (n  1679) Neutropenia Sensory neuropathy Hypertension Febrile neutropenia Venous thromboembolic event Proteinuria02.3 Arterial thromboembolic event Bleeding Left ventricular systolic function Wound dehiscence Fistula GI perforation RPLS0<0.1 RPLS=Reversible posterior leukoencephalopathy syndrome.

46 Grade ≥3 Selected Adverse Events (AEs), Pooled Population % Non-BV (n  982) BV (n  1679) Neutropenia Sensory neuropathy Hypertension Febrile neutropenia Venous thromboembolic event Proteinuria02.3 Arterial thromboembolic event Bleeding Left ventricular systolic funct Wound dehiscence Fistula GI perforation RPLS0<0.1 RPLS=Reversible posterior leukoencephalopathy syndrome.

Elderly Patients X Pivot, EJC 2011

TJ Smith, & BE Hillner, NEJM 2011

Cost-Effectiveness

Conclusions

Question 1: Bevacizumab is approved for first line therapy of MBC patients. Is this indication appropriate? Question 2: Do the results of the AVADO (Docetaxel) and/or RIBBOn-1 trials represent a favorable risk-benefit analysis for the upfront therapy of MBC? Question 3:Do the results of the RIBBOn-1 and AVADO trials confirm the Clinical Benefit of Bevacizumab in combination with Paclitaxel for the initial treatment of patients with HER2- MBC? Question 4: Will the PFS time no longer be accepted as an endpoint without QoL data?

Conclusions Neo-Angiogenesis is obviously important also in Breast Cancer Addition of Bevacizumab to CT results in a clear advantage in RR and PFS The advantage may be clinically very relevant in some situations (ie TNBC) Toxicity is manageable Age and other factors are little relevant Cost issue should be scientifically faced

[TITLE]